"Analysts Laud Viking Therapeutics' Soaring Stock on Positive Weight-Loss Drug Data"
Viking Therapeutics stock surged by 25% after announcing positive results from a phase 1 clinical study of its oral obesity drug VK2735, showing up to 3.3% placebo-adjusted mean weight loss and promising safety and tolerability. The company plans to advance the oral and injectable formulations of the drug into further testing, with expectations for strong pipeline prospects, making it a potential buy for aggressive investors.